Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Sep 04, 2026
Sprott Junior Uranium Miners ETF (URNJ) Climbs +27% Over 30 Days on Uranium Supply Concerns

Sprott Junior Uranium Miners ETF (URNJ) Climbs +27% Over 30 Days on Uranium Supply Concerns

Key Takeaways

  • URNJ has climbed roughly 27% over the trailing 30 days, rebounding from a late-July low near $20.88 to approximately $27.96.
  • The trailing quarter has been more volatile than the headline move suggests, with the fund roughly flat after a sharp mid-summer drawdown and recovery.
  • A firming uranium spot price, supply setbacks at Kazatomprom, and record long-term contract pricing have driven a re-rating of junior uranium miners.
  • Largest holdings NexGen Energy, Paladin Energy, Denison Mines, and Energy Fuels have led the rebound.
  • AI-driven nuclear demand and global reactor-expansion pledges support the structural thesis, while elevated volatility (beta near 1.5) remains a key risk.

Understanding the Sprott Junior Uranium Miners ETF (URNJ) and Its Holdings

The Sprott Junior Uranium Miners ETF (URNJ) is a passively managed, non-diversified exchange-traded fund that seeks to track the Nasdaq Sprott Junior Uranium Miners Index. The index focuses on companies that derive at least 50% of their revenue or assets from uranium mining, exploration, development, production, royalties, or supply. Launched in February 2023, the fund carries a net expense ratio of 0.80% and holds roughly 40 small- and mid-cap uranium equities, with approximately $326 million in assets under management as of mid-2026.

Portfolio exposure is concentrated. NexGen Energy (NXE), Paladin Energy, and Denison Mines (DNN) each represent roughly 12% of assets, followed by Energy Fuels (UUUU) near 9.5%. Smaller positions include Deep Yellow, IsoEnergy, Ur-Energy (URG), CGN Mining, Bannerman Energy, and Boss Energy. Geographically, the fund skews heavily toward Canada and Australia, with the United States a smaller but meaningful component. Because the underlying companies are junior miners with limited current production and high sensitivity to uranium prices, URNJ carries a beta of approximately 1.47 and exhibits substantially more volatility than broad equity benchmarks. I also checked this using Tickeron’s AI Screener to see how the fund compares to others in the industry.

URNJ's Recent Price Moves: 30 Days and the Quarter

Over the trailing 30 days, URNJ has advanced roughly 27%, moving from about $22.06 to approximately $27.96. The move was not a straight line but a sharp, momentum-driven recovery from the fund's late-July trough near $20.88.

The trailing three-month picture is more nuanced. URNJ ended the period essentially flat, having started near $28 in late May before declining roughly 25% into a late-July low and then rebounding about 34%. In other words, the 30-day gain largely retraced an earlier drawdown, leaving the fund near its late-May level. This V-shaped pattern reflects the sector's range-bound, high-volatility character rather than a steady trend.

Drivers Behind the Recent 30-Day Surge in URNJ

The recent surge was driven primarily by a tightening supply narrative and firmer uranium pricing. The U3O8 spot price broke out of a months-long range, rising to about $89.50 per pound — its highest level in roughly six months — after Kazatomprom, the world's largest uranium producer, disclosed further delays to its sulphuric acid plant in Kazakhstan. The company pushed commissioning to between the third quarter of 2027 and the first quarter of 2028, extending a key bottleneck in the fuel cycle.

Sentiment was reinforced by Kazatomprom's own commentary that the "era of cheap uranium" is ending, alongside long-term contract prices trading near 18-year highs of roughly $94–$95 per pound. Cameco (CCJ) added to the bullish tone by raising its 2026 realized uranium price guidance toward the mid-$90s per pound. A confidential S-1 filing for a potential Westinghouse initial public offering — backed by Cameco and Brookfield — further signaled institutional conviction in the nuclear fuel cycle, while reports of potential takeover interest in NexGen Energy underscored the strategic scarcity of Western uranium assets.

Within the portfolio, the largest positions — NexGen Energy (NXE), Paladin Energy, Denison Mines (DNN), and Energy Fuels (UUUU) — collectively account for roughly 45% of assets and led the move, amplifying the sector-wide repricing.

The Quarter's Broader Context for URNJ

The prior quarter told a more cautious story. After uranium's spot price spiked above $100 per pound early in 2026, it consolidated in the mid-$80s through the spring, and uranium equities de-rated as investors digested the gap between elevated equity valuations and a spot market that remained range-bound. URNJ declined steadily from late May into late July before stabilizing.

The August rebound reflected a shift from spot-price momentum toward long-term contracting fundamentals. Utilities stepped up term purchases, long-term prices climbed to multi-year highs, and supply-side frictions — including Kazakh project delays and Western Australian policy constraints on new mines — reinforced expectations of a structural deficit. This rotation from spot-driven speculation toward contract-backed demand underpinned the recovery in junior uranium miners, whose valuations are most leveraged to future production and price realization.

Looking Ahead for URNJ

The outlook for URNJ hinges on several structural themes rather than any single catalyst. Investors should monitor Kazatomprom's production execution and project timelines, as well as the pace and pricing of utility term contracting, which remains the clearest signal of long-term demand. Developments in AI and data-center procurement, the potential Westinghouse IPO, and permitting milestones at flagship projects such as NexGen Energy's Rook I and Denison Mines' Wheeler River will also shape sentiment.

On the macro side, interest-rate expectations and broad risk appetite can influence flows into a high-beta thematic fund, while policy decisions — including Western Australia's uranium mining stance and global reactor-expansion commitments — carry long-term supply and demand implications. The principal risk remains volatility: URNJ's small-cap, production-light exposure means the fund can move sharply in either direction on shifts in spot pricing or single-stock news. No near-term price outcome is guaranteed, but the fund's trajectory is most closely tied to the uranium market's evolving supply-demand balance and the durability of the nuclear fuel-cycle investment cycle.

Using AI Tools in Sector Analysis

In my own research process, I frequently rely on Tickeron's AI Screener to quickly scan for technical setups, volatility metrics, and sector momentum in areas like uranium. The platform helps surface relevant candidates and confirm trends without manual effort, which is especially useful for thematic funds like URNJ where price action can shift rapidly.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: URNJ

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


Momentum Indicator for URNJ turns negative, indicating new downward trend

URNJ saw its Momentum Indicator move below the 0 level on September 04, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 56 similar instances where the indicator turned negative. In 55 of the 56 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for URNJ turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 33 similar instances when the indicator turned negative. In 32 of the 33 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

URNJ moved below its 50-day moving average on September 11, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for URNJ crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where URNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for URNJ entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where URNJ's RSI Indicator exited the oversold zone, 14 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where URNJ advanced for three days, in 219 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

URNJ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Nasdaq Sprott Junior Uranium Miners Index. The fund will, under normal circumstances, invest at least 80% of its total assets in securities of the index. The index is designed to track the performance of companies that derive at least 50% of their revenue and/or assets from (i) mining, exploration, development, and production of uranium; (ii) earning uranium royalties; and/or (iii) supplying uranium. The index generally consists of from 30 to 40 constituents. The fund is non-diversified.

Market Cap

The average market capitalization across the Sprott Junior Uranium Miners ETF (URNJ) ETF is 11.96B. The market cap for tickers in the group ranges from 50.62M to 50.62M. FNUC holds the highest valuation in this group at 50.62M. The lowest valued company is FNUC at 50.62M.

High and low price notable news

The average weekly price growth across all stocks in the Sprott Junior Uranium Miners ETF (URNJ) ETF was 4%. For the same ETF, the average monthly price growth was -1%, and the average quarterly price growth was 15%. FNUC experienced the highest price growth at -11%, while FNUC experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Sprott Junior Uranium Miners ETF (URNJ) ETF was -1%. For the same stocks of the ETF, the average monthly volume growth was 18% and the average quarterly volume growth was 2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 67
P/E Growth Rating: 47
Price Growth Rating: 62
SMR Rating: 70
Profit Risk Rating: 83
Seasonality Score: 15 (-100 ... +100)
View a ticker or compare two or three
URNJ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category NaturalResources

Category
Natural Resources
Address
Sprott ETF Trust320 Post Road, Suite 230Darien
Phone
203-656-2400
Web
www.sprottetfs.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.